Esteve Pharmaceuticals has been granted a patent for oxadiazaspiro compounds that have pharmacological activity towards the sigma (s) receptor. These compounds can be used in therapy, specifically for treating drug abuse and addiction. GlobalData’s report on Esteve Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Esteve Pharmaceuticals, cancer treatment biomarkers was a key innovation area identified from patents. Esteve Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11649248B2) discloses a compound of general Formula (I) and its various derivatives. The compound can be represented by different forms, including (Ia'), (Ib'), (Ic'), and (I2'). The patent claims cover a wide range of variations in the compound's structure, including substitutions and unsubstituted forms of alkyl, cycloalkyl, aryl, and heterocyclyl groups.
The patent also describes a process for preparing the compound of Formula (I) through an intramolecular cyclization reaction. The process involves the use of a compound of formula VIIa as a starting material.
Furthermore, the patent claims encompass the use of the compound of Formula (I) or its pharmaceutically acceptable salt in a pharmaceutical composition. The composition includes a pharmaceutically acceptable carrier, adjuvant, or vehicle. This suggests that the compound may have potential therapeutic applications.
One specific application mentioned in the patent is the treatment of drug abuse or addiction. The patent claims that administering an effective amount of the compound of Formula (I) can be used to treat drug abuse or addiction in individuals who require such treatment.
Additionally, the patent includes a list of specific compounds that fall within the scope of the claims. These compounds have different structures and can be used as potential candidates for further research and development.
Overall, the granted patent provides protection for a compound of Formula (I) and its derivatives, as well as methods for their preparation and use in pharmaceutical compositions. The patent's claims cover a broad range of variations in the compound's structure, indicating potential versatility and applicability in various fields, including drug development and treatment of drug abuse or addiction.
To know more about GlobalData’s detailed insights on Esteve Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
